Publications by authors named "Giorgio Guglielmi"
Understanding the capability of a drug to penetrate the blood-brain barrier (BBB) is an unmet medical need in patients with positive human epidermal growth factor receptor 2 (HER2 positive) and brain metastases. The National Comprehensive Cancer Network (NCCN) guidelines recommend the use of tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib in co-administration with monoclonal antibodies or chemotherapy drugs and the antibody-drug conjugates (ADCs) trastuzumab-deruxtecan and trastuzumab-emtansine. Predicting the BBB permeability of these therapeutic agents is a pharmacological challenge due to the various factors involved in the barrier functions.
View Article and Find Full Text PDFArticle Synopsis
- - The treatment landscape for estrogen receptor (ER)-positive breast cancer includes various endocrine therapies like aromatase inhibitors, selective estrogen receptor modulators, and the recently approved selective estrogen receptor degraders (SERDs) like Fulvestrant.
- - Elacestrant is the first oral SERD approved by the FDA for specific cases of advanced breast cancer in postmenopausal women who have already undergone other treatments.
- - Current clinical trials are exploring additional oral SERDs, like amcenestrant and giredestrant, paving the way for new therapeutic options in managing ER-positive breast cancer.
Article Synopsis
- Researchers are looking for new biomarkers to predict how Crohn's disease patients respond to anti-TNF-α treatments, as many don't improve or lose effectiveness over time.
- In a study with 37 patients from a hospital in Italy, blood samples were analyzed to compare levels of specific microRNAs between those who responded to treatment and those who didn't.
- The findings suggest that lower levels of let-7e and miR-126 in blood samples could indicate a higher likelihood of clinical remission for patients receiving anti-TNF-α therapy.